360° SearchNetwork Hot Spots Trends Time Series

anthracycline

Type: Keyphrase

Name: anthracycline

First reported 23 hours ago - Updated 23 hours ago - 1 reports

CD73 promotes chemoresistance and poor survival [Immunology]

Using gene-expression data from over 6,000 breast cancer patients, we report herein that high CD73 expression is associated with a poor prognosis in triple-negative breast cancers (TNBC). Because anthracycline-based chemotherapy regimens are standard ... [Published PNAS - 23 hours ago]

Entities: Immunology, anthracycline, Breast Cancer, antineoplastic

First reported Jun 12 2013 - Updated Jun 13 2013 - 2 reports

capecitabine

Chemotherapy: Greater potential benefit in overall survival for eribulin compared with capecitabine

The specific patient populations who appeared to benefit from eribulin, in comparison to capecitabine, are as follows:Patients with more than two organs involved with metastatic breast cancerPatients who had not received chemotherapy for six months or ... [Published Science Daily - Jun 13 2013]

Entities: Eribulin, capecitabine, Chemotherapy, Metastatic

First reported Jun 10 2013 - Updated Jun 10 2013 - 2 reports

MRI detects early heart chemo damage

Detecting early damage to a child's heart following chemotherapy is possible using MRI scans, says a study from Canada. Even when children's heart function appeared to be normal, a new MRI method of mapping the heart was able to identify damage, University ... [Published BBC - Jun 10 2013]

Entities: Magnetic Resonance Imaging, Chris Plummer, Chemotherapy, anthracycline

First reported Jun 06 2013 - Updated Jun 06 2013 - 3 reports

Celgene Corporation

Celgene Corporation gets US FDA's approval for REVLIMID for treating relapsed or refractory mantle cell lymphoma

Biopharmaceutical company Celgene Corporation (NasdaqGS:CELG) revealed on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for REVLIMID (lenalidomide) for the treatment of ... [Published Individual.com - Jun 06 2013]

Entities: Celgene Corporation, Lenalidomide, mitoxantrone, FDA Food & Drug Administration, open label study

First reported May 30 2013 - Updated May 31 2013 - 2 reports

Sunesis Pharmaceuticals Inc

Vosaroxin Review Published in Expert Opinion on Pharmacotherapy

(GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of a peer-reviewed paper in Expert Opinion on Pharmacotherapy featuring the Company's lead product candidate, vosaroxin. In addition to an overview of the ... [Published Big News Network - May 31 2013]

Entities: Pharmacotherapy, anthracycline, Sunesis Pharmaceuticals Inc

First reported May 28 2013 - Updated May 28 2013 - 1 reports

Hybrid photoactive fullerene derivative-ruboxyl nanostructures for photodynamic therapy

Here we report the investigation of photophysical properties and photodynamic action of two novel water soluble hybrid molecular structures based on [60]fullerene dyads bearing covalently attached residues of anthracycline antibiotic “ruboxyl”. Molecular ... [Published RSC - May 28 2013]

Entities: Fullerene, photodynamic therapy, Spectroscopy, anthracycline

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Intensified, Liposomal Anthracycline-Based Chemo Regimen for Children with Leukemia May Offer High Survival Rates Without Added Heart Toxicity

/PRNewswire-USNewswire/ -- Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ... [Published TickerTech.com - May 23 2013]

Entities: idarubicin, Patient, liposomal

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Eisai files application with EMA for indication expansion of anticancer agent

Eisai Europe Ltd., the UK subsidiary of Eisai Co., Ltd., has filed an application with the European Medicines Agency, or EMA, for anticancer agent Halaven, or eribulin mesylate, requesting an indication expansion of eribulin to contribute to earlier-line ... [Published Individual.com - May 20 2013]

Entities: Eribulin, Eisai Co Ltd, European Medicines Agency, Metastatic, antineoplastic

First reported Apr 02 2013 - Updated Apr 02 2013 - 1 reports

Biocodex USA Acquires Totect®, Antidote for Unintended Tissue Damage from Chemotherapy Business Wire

SAN BRUNO, Calif.--(BUSINESS WIRE)-- Biocodex USA announced today its acquisition of the oncology supportive care product, Totect® from Apricus Biosciences. Totect® (dexrazoxane HCl) is the only FDA-approved treatment for anthracycline extravasation, ... [Published Yahoo! Finance - Apr 02 2013]

Entities: Biocodex, Chemotherapy, Antidote, anthracycline, Oncology

Quotes

...Theurer Cancer Center at Hackensack UMC and Chief Science Officer and Director of Research and Innovation at Regional Cancer Care Associates, LLC. "The approval of lenalidomide delivers a new option, and the first oral therapy in this area of lymphoma."

Celgene's sNDA for mantle cell lymphoma drug receives FDA approval [Published Individual.com - Jun 17 2013]

"These exploratory analyses suggest that other patient subgroups may benefit from eribulin and further studies are warranted" said Peter A Kaufman, MD, associate professorprofessor of medicine at the Geisel School of Medicine at Dartmouth, and oncologist at Dartmouth-Hitchcock...

Chemotherapy: Greater potential benefit in overall survival for eribulin compared with capecitabine [Published Science Daily - Jun 13 2013]

...Plummer said, "We have to look for ways to protect the heart and intervene earlier when damage occurs. Waiting for visible heart damage to appear is too long to wait." He says MRI with T1 mapping is an “excellent way of precisely monitoring heart function in children,” and the scans are “entirely safe”...

Safe MRI detects chemotherapy heart damage early for children [Published Digital Journal - Jun 10 2013]

Dr Edythe Tham and Dr Richard Thompson, who led the study, said: "In childhood cancer survivors, MRI changes were related to anthracycline dose given to the children. "These changes are also mirrored by thinning of the heart wall and a reduction in the exercise capacity." Dr Chris Plummer, consultant cardiologist at the Freeman Hospital in Newcastle, said the side effects of chemotherapy were well-known. "Chemotherapy with anthracyclines is a very effective treatment for cancer but it can be quite toxic to the heart. "We've known that for a long time but the number of children affected is only becoming appreciated now. "We have to look for ways to protect the heart and intervene earlier when damage occurs. "Waiting for visible heart damage to appear is too long to wait." But Dr Plummer said carrying out an MRI scan of a child's heart was not an easy thing to do. "Scanning the heart is more difficult than other organs because it is constantly in motion. But with modern scanners the images are fantastic. "It's the best way of looking at the structure and function of the heart - and it's entirely safe. "It is an excellent way of precisely monitoring heart function in children.""

MRI detects early heart chemo damage [Published BBC - Jun 10 2013]

More Content

sort by: Date \| Relevance
CD73 promotes chemoresistance and poor survival... [Published PNAS - 23 hours ago]
Postmenopausal Hormone Receptor–Positive Advanc... [Published Cancernetwork.com - Jun 18 2013]
Celgene's sNDA for mantle cell lymphoma drug re... [Published Individual.com - Jun 17 2013]
U.S. Food and Drug Administration Approves REVL... [Published Pharmacy Choice - Jun 17 2013]
Chemotherapy: Greater potential benefit in over... [Published Science Daily - Jun 13 2013]
Study finds greater potential benefit in overal... [Published Bio-Medicine - Jun 12 2013]
Glaxo Reports Disappointing Tykerb Data Zacks [Published Yahoo! Finance - Jun 10 2013]
Safe MRI detects chemotherapy heart damage earl... [Published Digital Journal - Jun 10 2013]
MRI detects early heart chemo damage [Published BBC - Jun 10 2013]
MRI detects early effects of chemotherapy on ch... [Published Medical Xpress - Jun 10 2013]
Zacks Bull and Bear of the Day Highlights: Muel... [Published Yahoo! Finance - Jun 06 2013]
Celgene Corporation gets US FDA's approval for ... [Published Individual.com - Jun 06 2013]
FDA clears Celgenes sNDA for mantle cell lympho... [Published Big News Network - Jun 06 2013]
Celgene’s Revlimid Wins FDA Approval for Mantle... [Published Pharma-Mag - Jun 06 2013]
FDA Approves Lenalidomide for the Treatment of ... [Published OncLive - Jun 06 2013]
Nektar Presents Data on Oncology Candidates Zacks [Published Yahoo! Finance - Jun 05 2013]
U.S. Food and Drug Administration Approves Celg... [Published Reuters - Jun 05 2013]
Celgene Corporation (CELG): FDA OKs Revlimid To... [Published I Stock Analyst - Jun 05 2013]
Celgene Says FDA Approves REVLIMID For Treatmen... [Published RTTNews.com - Jun 05 2013]
Eisai presents new QOL findings in pateints wit... [Published PharmaBiz - Jun 04 2013]
Analyses of MPACT Trial Evaluating ABRAXANE® Co... [Published BioPortfolio - Jun 03 2013]
6/3/13 - Celgene Announces U.S. FDA Grants Prio... [Published Pharmacy Choice - Jun 03 2013]
Study Shows Improved Overall Quality of Life Wi... [Published FinanzNachrichten.de - Jun 03 2013]
Nektar Announces Target-Specific Biomarkers Bei... [Published Benzinga.com - Jun 01 2013]
Vosaroxin Review Published in Expert Opinion on... [Published Big News Network - May 31 2013]
Sunesis Pharmaceuticals, Inc. (SNSS) Release: V... [Published BioSpace - May 30 2013]
Vosaroxin Review Published in Expert Opinion on... [Published Nasdaq - May 30 2013]
Chemosensetizing and cardioprotective effects o... [Published Cancer Cell International - May 28 2013]
New Market Research Report: Apricus Biosciences... [Published Live-PR.com - May 28 2013]
Hybrid photoactive fullerene derivative-ruboxyl... [Published RSC - May 28 2013]

Blogs

sort by: Date \| Relevance
Celgene’s Revlimid Wins FDA Approval for Mantle... [Published Pharma-Mag - Jun 06 2013] FDA cleared Celgene’s supplemental new drug application (sNDA) for Revlimid® (lenalidomide) as a treatment for mantle cell lymphoma in patients whose disease has relapsed or progressed after two prior therapies, one of which included bortezomid. Approval ...
Deals of the Week: An Update On A Potential Pfi... [Published The IN VIVO Blog - Mar 29 2013] br /> Pfizer's Chairman and CEO Ian Read doesn’t make himself available for interviews readily, so a March 26th note from Sanford Bernstein’s esteemed pharma analyst Tim Anderson caught our attention pronto. The note describes a teleconference call ...

Press Releases

sort by: Date \| Relevance
Samenvatting: Biocodex USA neemt Totect over; e... [Published Business Wire Health News - Apr 02 2013]
Biocodex USA Acquires Totect®, Antidote for Uni... [Published Business Wire Health News - Apr 02 2013]
DGAP-News: Apricus Biosciences Announces Sale o... [Published GlobeNewswire: Acquisitions News - Apr 01 2013]